文献速递类风湿关节炎

类风湿关节炎中Janus激酶抑制剂对比生物改善病情抗风湿药的糖皮质激素节约效应:单中心回顾性分析

Glucocorticoid sparing effect of Janus kinase inhibitors compared to biologic disease modifying anti-rheumatic drugs in rheumatoid arthritis, a single-centre retrospective analysis.
PubMed 文献 · Rheumatology (Oxford) · 2025-01-01

本单中心回顾性分析纳入716例接受JAKi(n=156)或bDMARDs(n=560)治疗的类风湿关节炎患者,评估糖皮质激素减量、挽救治疗及停用情况。JAKi组前6个月激素剂量下降更快,停用激素的校正比值比为1.63(95%CI 1.02, 2.60,P=0.039),12个月后超过50%的JAKi治疗患者停用激素,而bDMARDs组约为40%。bDMARDs组需要激素挽救治疗的比率显著更高(率比2.66,95%CI 1.88, 3.74)。

要点

  • JAKi组前6个月激素剂量下降较bDMARDs组更快。
  • JAKi组停用激素的校正OR为1.63(95%CI 1.02, 2.60,P=0.039)。
  • bDMARDs组激素挽救治疗率比JAKi组高(率比2.66,95%CI 1.88, 3.74)。

核心结论

  • 本研究发现,在类风湿关节炎患者中,JAKi较bDMARDs促进更快速的糖皮质激素减量。
  • 这些结果强调JAKi在减少长期糖皮质激素暴露方面的潜在价值,包括减少糖皮质激素相关不良反应。

研究设计与样本

  • 本研究为单中心回顾性分析,纳入接受JAKi或bDMARDs治疗的类风湿关节炎患者。
  • 共评估716例患者,其中JAKi组156例,bDMARDs组560例。
  • 采用混合效应模型分析激素减量,泊松回归分析挽救治疗,多变量逻辑回归分析停药,并校正基线疾病活动度、人口学因素和治疗线。

主要发现

  • JAKi组在治疗前6个月内激素剂量下降较bDMARDs组更快。
  • JAKi组停用激素的校正OR为1.63(95%CI 1.02, 2.60,P=0.039),高于bDMARDs组。
  • 尽管JAKi组基线激素剂量更高,12个月后超过50%的JAKi治疗患者停用激素,而bDMARDs组约为40%。
  • bDMARDs组需要激素挽救治疗的率比显著高于JAKi组(率比2.66,95%CI 1.88, 3.74)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Glucocorticoid sparing in rheumatoid arthritis (RA) treatment is crucial to minimizing adverse effects associated with long-term use. Janus kinase inhibitors (JAKi) could potentially offer a more potent glucocorticoid-sparing effect than biologic DMARDs (bDMARDs). MATERIAL AND METHODS: This is a single-centre retrospective analysis of RA patients treated with JAKi or bDMARDs. Glucocorticoid tapering, rescue therapy and discontinuation were analysed through mixed-effects models, Poisson regression and multivariable logistic regression, respectively, adjusting for baseline disease activity, demographic factors and treatment line. RESULTS: A total of 716 RA patients treated with JAKi (n = 156) or bDMARDs (n = 560) were evaluated. JAKi treatment was associated with a more rapid reduction in glucocorticoid dose within the first 6 months and 60% higher odds of discontinuation compared with bDMARDs (adjusted odds ratio 1.63; 95% CI: 1.02, 2.60, P = 0.039). Despite a higher baseline glucocorticoid dose, over 50% of JAKi-treated patients discontinued glucocorticoids after 12 months, vs ∼40% for bDMARDs. The need for glucocorticoid rescue therapy was significantly higher in the bDMARD group (rate ratio 2.66; 95% CI: 1.88, 3.74). CONCLUSION: Our findings indicate that JAKi facilitate more rapid glucocorticoid tapering compared with bDMARDs in RA patients. These results underscore the potential of JAKi to reduce long-term glucocorticoid exposure, highlighting their value in RA management strategies, including minimizing glucocorticoid-related adverse effects.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Adami G, Bixio R, Virelli G, et al. Glucocorticoid sparing effect of Janus kinase inhibitors compared to biologic disease modifying anti-rheumatic drugs in rheumatoid arthritis, a single-centre retrospective analysis. Rheumatology (Oxford). 2025. PMID: 39167121. doi:10.1093/rheumatology/keae455

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。